

Serial No.: 09/293,670

Filed: April 16, 1999

At page 50, line 17, replace "othewise" with --otherwise--.

At page 50, line 20, replace "exocytosa" with --exocytose--.

At page 50, line 28, replace "enyme" with --enzyme--.

At page 50, line 34, replace "activty" with --activity--.

At page 51, line 3, replace "cytomoter" with --cytometer--.

At page 51, line 5, replace "acitivity" with --activity--.

At page 51, lines 7, 10, 15, 19, 21, 29, 33, 34 and 35, replace "Lysotracker" with --LYSOTRACKER™--.

At page 52, line 33, replace "12" with --13--.

At page 52, line 37, replace "concensus" with --consensus--.

At page 53, line 17, replace "retrolral" with --retroviral--.

At page 53, line 22, replace "concensus" with --consensus-- and "faciltate" with --facilitate--.

At page 55, lines 1 and 5, replace "supermatant" with --supernatant--.

IN THE CLAIMS

1. (Amended) A method of screening for a bioactive agent capable of altering a cellular phenotype, said method comprising:

a) combining at least one candidate bioactive agent and a population of cells; and

b) sorting said cells in a FACS machine by separating said cells on the basis of at least five cellular parameters which allow detection of alterations in cellular phenotype, whereby said alteration in cellular phenotype indicates said candidate is a bioactive agent capable of altering a cellular phenotype.

3. (Amended) A method of screening for a bioactive agent capable of altering a cellular phenotype, said method comprising:

a) introducing a library of nucleic acids each encoding a candidate bioactive agent into a population of cells; and

b) sorting said cells in a FACS machine by separating said cells on the basis of at least three cellular parameters which allow detection of alterations in cellular

Serial No.: 09/293,670

Filed: April 16, 1999

B3 Cont sub and } phenotype, whereby said alteration in cellular phenotype indicates said candidate is a bioactive agent capable of altering a cellular phenotype.

B4 5. (Amended) A method according to claim 3 [or 4] wherein said cellular phenotype is exocytosis and said cellular parameters are selected from the group consisting of light scattering, fluorescent dye uptake, fluorescent dye release, annexin granule binding, surface granule enzyme activity, and the quantity of granule specific proteins.

7. (Amended) A method according to claim 3 [or 4] wherein said cellular phenotype is cell cycle regulation and said cellular parameters comprise cell viability, proliferation, and cell phase.

B5 8. (Amended) A method according to claim 3, 4, 5, 6, [or] 7, 11, 12 or 13 wherein said nucleic acids comprise fusion nucleic acids comprising:
a) said nucleic acid encoding said candidate bioactive agents; and
b) a detectable moiety.

9. (Amended) A method according to claim [1, 2, 3, 4, 5, 6, 7 or 8] 1 or 2 wherein said cells are tumor cells.

Please add the following new claims:

B6 --11. A method according to claim 4 wherein said cellular phenotype is exocytosis and said cellular parameters are selected from the group consisting of light scattering, fluorescent dye uptake, fluorescent dye release, annexin granule binding, surface granule enzyme activity, and the quantity of granule specific proteins.

12. A method according to claim 11 further comprising subjecting said cells to conditions that normally cause exocytosis.